Society for Immunotherapy of Cancer (SITC)

MILWAUKEE (PRWEB) August 12, 2022

The Society for Immunotherapy of Cancer (SITC) Forward Fund is pleased to announce the recipients of the 2022 Fellowships and Technology Awards, which support the next generation of cancer immunotherapy and tumor immunology experts through dedicated funding of novel research.

Together with the immense generosity of our supporters, SITC is honored to help young investigators realize their cancer immunotherapy research dreams, said SITC President Patrick Hwu, MD. It is our hope that these young researchers turn their dreams and cure into a reality for all cancer patients.

These awards are financially supported through the Forward Fund, which was established by SITC in 2012 to stimulate the future of science, development and application of cancer immunology and immunotherapy through financially supporting its education and research. Since 2014, SITC has awarded more than $5 million in funding to deserving early career scientists in the field of cancer immunotherapy.

The 2022 SITC Fellowship and Technology Award recipients are:

SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational FellowshipAward Amount: $200,000 (two-year)Awardee: Simone Minnie, PhDInstitution: Fred Hutchinson Cancer Research Center Project Title: Harnessing Treg fragility to improve anti-myeloma immune responses

SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies FellowshipAward Amount: $100,000 (one-year)Awardee: John Ligon, MDInstitution: University of FloridaProject Title: Leveraging CD70 CXCR2-modified CAR T-cells for treating AML

SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical FellowshipAward Amount: $100,000 (one-year)Awardee: Jonathan Chen, MD, PhDInstitution: Massachusetts General HospitalProject Title: Dissecting the tumor immunity multicellular network

SITC-Merck Cancer Immunotherapy Clinical FellowshipAward Amount: $100,000 (one-year)Awardee: Hitomi Hosoya, MD, PhDInstitution: Stanford UniversityProject Title: Cell-free DNA-based Platform to Determine Treatment Response and Resistant Mechanisms to CAR T-cell Therapy in Multiple Myeloma

SITC-Genentech Women in Cancer Immunotherapy FellowshipAward Amount: $50,000 (one-year)Awardee: Shu-chin Lai, PhDInstitution: Huntsman Cancer Institute, University of UtahProject Title: Augmenting T cell immunity to facilitate metastatic breast cancer treatment

SITC-Nektar Therapeutics Equity and Inclusion in Cancer Immunotherapy FellowshipAward Amount: $50,000 (one-year)Awardee: Mara De Martino, PhDInstitution: Weill Cornell MedicineProject Title: Targeting FASN to sensitize irradiated glioblastoma to immunotherapy

SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical FellowshipAward Amount: $40,000 (one-year)Awardee: Steven Blum, MDInstitution: Dana-Farber Cancer Institute, Massachusetts General HospitalProject Title: Distinguishing Immune-Related Adverse Events (irAEs) from Anti-Tumor Immunity

SITC-Natera ctDNA in Immunotherapy Response Monitoring Fellowship and Technology AwardAward: $40,000 and access to Nateras Signatera testing technology Awardee: Mariya Rozenblit, MDInstitution: Yale UniversityProject Title: The tumor microenvironment of triple negative breast cancers with detectable circulating tumor DNA after pembrolizumab treatment

SITC-NanoString Technologies Single Cell Biology AwardAward: Access to NanoString Technologies CosMx Spatial Molecular Imager (SMI)Awardee: Elshad Hasanov, MD, PhDInstitution: University of Texas MD Anderson Cancer CenterProject Title: CosMxing renal cell carcinoma brain metastases to decipher immune checkpoint inhibitor resistance mechanisms at single-cell and spatial context

This years SITC Forward Fund Fellowships and Technology Awards were made possible through the generosity of Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, Mallinckrodt Pharmaceuticals, Merck, Nektar Therapeutics, NanoString Technologies and Natera Technologies. The fellowship and technology award recipients will be honored during a ceremony at the societys 37th Annual Meeting at the Boston Convention and Exhibition Center in Boston, Massachusetts.

To learn more about current and past SITC Fellowship and Technology Award recipients, visit SITCs website.

About SITCEstablished in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word cure a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

Share article on social media or email:

View original post here:
Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships and Technology Awards - PR Web